Study of a CD19 CAR T-cell treatment for relapsed leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age: you must be at least 3 years old and under 70 (or at least 18 for the lymphoma part).
- Your cancer must be CD19-positive B-ALL (or, for the lymphoma part, certain relapsed/refractory B-cell lymphomas).
- Your disease must be relapsed or refractory, such as not reaching remission or remission lasting no more than 12 months for B-ALL.
- Your bone marrow must contain enough cancer cells (over 5% by microscope and/or over 1% by flow testing).
- You must not have certain brain/spread patterns (except specific controlled CNS involvement for B-ALL).
- Your body must be healthy enough for treatment: no serious lung infection, oxygen level ≥92% on room air, and good heart function (LVEF ≥50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This early-phase study tests “humanized” CD19 CAR-T therapy for people whose B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma (NHL) has come back or didn’t respond. It’s designed to help the immune system recognize and attack cancer cells carrying the CD19 marker.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.